Tech Company Financing Transactions
CRISPR Therapeutics Funding Round
Celgene, SR One Capital Management and Abingworth invested in a $64 million Series B venture round for CRISPR Therapeutics. The round closed on 4/30/2015.
Transaction Overview
Celgene (Lead Investor)
SR One Capital Management (Lead Investor) (Simeon George)
Abingworth (Kurt von Emster)
New Enterprise Associates (Ali Behbahani)
Versant Ventures (Brad Bolzon)
Company Information
Cambridge, MA 02139
USA
Management Team
Browse more venture capital transactions:
Prev: 4/30/2015: PlateJoy venture capital transaction
Next: 4/30/2015: ThreatQuotient venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs